Evidence map›Paper›PMID 40713699›Full record

Trial reportReproductive biology and endocrinology : RB&E2025

Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial.

Haiyan Chen, Xiaohui Lei, Zhuoran Yang, Yuxin Xu, Dongfang Liu, Cong Wang, Hu Du

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Reproductive biology and endocrinology : RB&E, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Haiyan ChenDepartment of Endocrinology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.
Xiaohui LeiDepartment of Endocrinology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.
Zhuoran YangDepartment of Endocrinology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.
Yuxin XuDepartment of Endocrinology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.
Dongfang LiuDepartment of Endocrinology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.
Cong WangDepartment of Endocrinology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China. congwang@hospital.cqmu.edu.cn.
Hu DuDepartment of Critical Care Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China. hudu@hospital.cqmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aimed to assess the effects of metformin (MET) monotherapy versus a combination of semaglutide and MET on weight, metabolism, reproductive function, and inflammatory markers in women with polycystic ovary syndrome (PCOS).

methodsA total of 100 overweight or obese women with PCOS diagnosed according to the Rotterdam criteria were randomly assigned to two groups: MET (1000 mg twice daily [BID] for 16 weeks) and combination therapy (COM) (1000  mg MET BID plus 1- mg semaglutide once weekly [QW] for 16 weeks). Primary outcomes, assessed at Week 0 and Week 16, included changes in anthropometric measures related to obesity, while the secondary outcomes included alterations in reproductive hormone levels, glucose and lipid metabolism, and C-reactive protein (CRP) levels, Between Weeks 16 and 40, all participants received metformin monotherapy (1000 mg BID) to evaluate pregnancy outcomes.

resultA total of 80 participants (80%) completed the study. After 16 weeks of intervention, the COM group exhibited significantly greater reductions in body weight, BMI, and waist-to-hip ratio (WHR) compared to the MET group (all P < 0.01). The COM group experienced an average weight loss of 6.09 ± 3.34 kg, while the MET group lost only 2.25 ± 4.27 kg. The COM group also demonstrated greater improvements in testosterone (TEST), Chinese visceral adiposity index (CVAI), and CRP levels compared to the MET group. Additionally, the COM group showed higher rates of menstrual cycle recovery than the MET group. From weeks 16 to 40, the COM group demonstrated a significantly higher natural pregnancy rate than the MET group (35% vs. 15%, P < 0.05).

conclusionCompared to MET monotherapy, combination therapy with semaglutide and MET significantly reduced body weight, improved insulin resistance, decreased inflammatory markers, alleviated and menstrual irregularities and increased natural pregnancy rates in overweight/obese women with PCOS. CLINICAL

trial registrationchictr.org.cn ID: ChiCTR2400090908 (Registration time: 2024-10-15).

Indexed as

Body WeightGlucagon-Like PeptidesHypoglycemic AgentsMetforminObesityOverweightPolycystic Ovary SyndromeAdultDrug Therapy, CombinationFemaleGlucagon-Like Peptide 1HumansPregnancyPregnancy OutcomeProspective StudiesReproductionGlucagon-Like Peptide 1Glucagon-Like PeptidesHypoglycemic AgentsMetforminSemaglutideMetforminPolycystic ovary syndromePregnancy outcomesSemaglutide

Identifiers

PMID40713699
PMCPMC12297736

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.